CVS Health (CVS) Stock Overview
Provides health solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
CVS Community Fair Values
Create NarrativeSee what 425 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CVS Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$102.08 |
| 52 Week High | US$106.15 |
| 52 Week Low | US$58.50 |
| Beta | 0.60 |
| 1 Month Change | 6.41% |
| 3 Month Change | 30.50% |
| 1 Year Change | 53.09% |
| 3 Year Change | 47.17% |
| 5 Year Change | 24.76% |
| Change since IPO | 15,448.60% |
Recent News & Updates
Seeking Alpha • Jul 06
CVS Health: The Surprising Healthcare Outlier
Summary CVS Health Corporation has outperformed peers, overcoming industry headwinds through effective management and strategic execution. CVS delivered a Q1 beat-and-raise, expects margin expansion in 2026, and projects low double-digit investor returns. While Health Services and Insurance segments anticipate mid-single-digit growth, retail is set for gradual decline but with margin improvements. At $105, CVS trades at a premium to its historical average but remains discounted versus peers, justifying a reiterated 'Buy' rating. Read the full article on Seeking Alpha
Narrative Update • Jun 24
CVS: Medicare Advantage Margins And GLP‑1 Programs Will Shape Future Earnings
Analysts have raised the implied fair value for CVS Health from about $102.85 to roughly $105.38. This change reflects higher Street price targets tied to expanding GLP-1 support programs, a calmer policy backdrop for managed care, and expectations for steadier earnings power across the business.Recent updates
Seeking Alpha • Jul 06
CVS Health: The Surprising Healthcare Outlier
Summary CVS Health Corporation has outperformed peers, overcoming industry headwinds through effective management and strategic execution. CVS delivered a Q1 beat-and-raise, expects margin expansion in 2026, and projects low double-digit investor returns. While Health Services and Insurance segments anticipate mid-single-digit growth, retail is set for gradual decline but with margin improvements. At $105, CVS trades at a premium to its historical average but remains discounted versus peers, justifying a reiterated 'Buy' rating. Read the full article on Seeking AlphaNarrative Update • Jun 24
CVS: Medicare Advantage Margins And GLP‑1 Programs Will Shape Future Earnings
Analysts have raised the implied fair value for CVS Health from about $102.85 to roughly $105.38. This change reflects higher Street price targets tied to expanding GLP-1 support programs, a calmer policy backdrop for managed care, and expectations for steadier earnings power across the business.Narrative Update • Jun 03
CVS: Medicare Advantage Margin Recovery Will Shape Future Earnings Profile
Narrative Update Analysts have nudged the CVS Health fair value estimate from $101.58 to $102.85, reflecting a series of higher price targets in the $106 to $110 range as they highlight margin recovery in government businesses, steadier pharmacy and pharmacy benefit manager earnings after reform, and supportive Q1 medical cost trends. Analyst Commentary Recent Street research on CVS Health clusters around a similar message, with several firms lifting price targets into a tighter band and pointing to company specific factors rather than broad sector calls.Analysis Article • May 18
Investors Can Find Comfort In CVS Health's (NYSE:CVS) Earnings Quality
CVS Health Corporation's ( NYSE:CVS ) stock was strong despite it releasing a soft earnings report last week. However...Narrative Update • May 15
CVS: Medicare Advantage Turnaround And PBM Clarity Will Shape Future Earnings Profile
Analysts have lifted the fair value estimate for CVS Health by $5 to $101.58, reflecting a series of higher price targets around $106 that emphasize expectations for a Medicare Advantage turnaround, steadier pharmacy and pharmacy benefit manager earnings, and reduced regulatory uncertainty after recent PBM reform and Federal Trade Commission actions. Analyst Commentary Recent Street research on CVS Health has become more constructive, with a cluster of higher price targets around $106 and several rating upgrades that feed directly into the higher fair value estimate.Analysis Article • May 08
CVS Health Corporation Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
CVS Health Corporation ( NYSE:CVS ) defied analyst predictions to release its quarterly results, which were ahead of...Narrative Update • Apr 22
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Future Earnings
CVS Health's analyst price targets have edged higher by a few dollars, as analysts factor in slightly stronger revenue and margin assumptions, a modestly lower discount rate, and a somewhat lower future P/E multiple in light of recent research that highlights Medicare Advantage exposure, potential earnings stability in pharmacy, and reduced regulatory uncertainty tied to a possible FTC settlement. Analyst Commentary Recent research on CVS Health reflects a mix of cautious optimism and ongoing concern, with analysts adjusting price targets by only a few dollars in either direction as they reassess earnings quality, regulatory risks, and Medicare Advantage exposure.Narrative Update • Apr 08
CVS: Medicare Advantage Turnaround Will Support Future Earnings Recovery
Analysts have trimmed the average CVS Health price target by a few dollars to around the mid $90s. This reflects slightly softer revenue growth assumptions, modestly higher margin expectations, and updated views on Medicare Advantage and regulatory risks following recent CMS and FTC related commentary.Narrative Update • Mar 25
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Earnings Recovery
Analysts have slightly raised their fair value estimate for CVS Health to $96.50, citing improving clarity around potential FTC settlements and a perceived Medicare Advantage turnaround. These developments could support a higher future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Narrative Update • Mar 11
CVS: Medicare Advantage Policy And Rates Will Support Future Earnings Recovery
Analysts have adjusted their price targets on CVS Health modestly lower. Our updated fair value estimate has moved from about $94.84 to roughly $96.38 per share.Narrative Update • Feb 24
CVS: Medicare Advantage And Great Healthcare Plan Will Support Future Margin Recovery
Analysts have trimmed their average price target on CVS Health by a few dollars, citing updated views on Medicare-related policy risks and a slightly lower future P/E assumption, even as they factor in modestly stronger profit margins over time. Analyst Commentary Recent research on CVS Health reflects a mix of optimism around long term earnings potential and caution around policy and reimbursement risk tied to Medicare and broader health reform proposals.Narrative Update • Feb 09
CVS: Medicare Advantage And Great Healthcare Plan Will Drive Earnings Recovery
Analysts have trimmed their fair value estimate for CVS Health by about $0.20 to $94.76, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and updated sector views after recent price target reductions and commentary around Medicare Advantage and managed care rates. Analyst Commentary Recent Street research around CVS Health centers on Medicare Advantage rate visibility, the outlook for managed care earnings, and shifting expectations for health policy.Narrative Update • Jan 23
CVS: Medicare Advantage And Great Healthcare Plan Will Support Earnings Rebound
Analysts have nudged their average price targets for CVS Health higher, with increases such as Bernstein moving to $91 from $87, BofA to $100 from $89, and RBC to $93 from $81. These changes reflect views that recent policy developments and Q3 results support a steadier outlook for government managed care earnings and potential catalysts in Medicare Advantage.
Narrative Update • Jan 09
CVS Health: Rebuilding a Healthcare Giant From the Inside Out
CVS Health (NYSE: CVS) has not been an easy stock to own. Over the past year, investors have watched margins compress, guidance get revised, and sentiment sour as healthcare cost inflation collided with reimbursement pressure.Narrative Update • Jan 08
CVS: Medicare Advantage Margin Recovery From 2026 Will Drive Earnings Rebound
Narrative Update Analysts have raised their blended price target on CVS Health by about $1, citing recent target increases into the low to mid $90s and $100 range. They also note views that Medicare Advantage and broader managed care earnings could enter recovery phases beginning around 2026, despite expected bumps along the way.Narrative Update • Dec 23
CVS: Medicare Advantage Margin Recovery Is Expected To Drive Earnings Momentum From 2026
Analysts have modestly raised their price target on CVS Health, with our fair value estimate increasing from approximately $92.44 to $94.33. This reflects growing confidence in earnings visibility, margin recovery in Medicare Advantage, and supportive recent EPS revisions despite mixed near term trends.Narrative Update • Dec 09
CVS: Medicare Advantage Margin Recovery Will Drive Earnings Momentum From 2026
The analyst price target for CVS Health has edged higher by about $1 to approximately $92, as analysts point to resilient earnings, improving visibility in Medicare Advantage margins, and a solid Q3 performance as support for modestly stronger long term valuation assumptions. Analyst Commentary Research updates highlight a generally constructive view on CVS Health, with multiple firms lifting price targets and emphasizing improved earnings visibility and margin recovery potential over the medium term.Narrative Update • Nov 25
CVS: Margin Recovery in Medicare Advantage Will Drive Earnings Momentum Through 2026
The analyst price target for CVS Health has been revised slightly lower from $91.52 to $91.48. Analysts point to a mixed quarterly report and evolving expectations around Medicare Advantage and earnings visibility as factors behind the update.Narrative Update • Nov 08
CVS: Earnings Momentum Will Drive Performance as Regulatory Shifts Unfold
Analysts have raised their fair value estimate for CVS Health to $91.52 from $86.20. This adjustment is due to improved earnings visibility and continued momentum following solid quarterly results.Narrative Update • Oct 25
Managed Care Margin Recovery And Healthcare Benefits Will Shape Industry Prospects
Analysts have raised their fair value estimate for CVS Health to $86.20. This modest increase is supported by greater earnings visibility and expectations for margin recovery in the managed care sector.Narrative Update • Oct 10
Digital Health Transformation And Integrated Care Will Expand Reach
Analysts have raised their price target for CVS Health, increasing it by nearly $2 to approximately $84 per share. They cite improved earnings visibility and strengthening fundamentals in the healthcare sector as key reasons for the change.Narrative Update • Sep 04
Digital Health Transformation And Integrated Care Will Expand Reach
Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.Analysis Article • Aug 13
CVS Health's (NYSE:CVS) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with CVS Health Corporation's ( NYSE:CVS ) lackluster earnings report last week. We...Seeking Alpha • Mar 30
CVS Health: I Don't Understand The Fuss, But The Worst Is Behind
Summary CVS Health experienced a significant turnaround in 2025, with shares up nearly 50% after a 44% decline in 2024. The recent rally is not driven by great results or strong guidance under new CEO leadership, but rather bad ones that just weren't as terrible as expected. CVS's 2025 outlook includes modest revenue growth, improved operating income, and a focus on stabilizing margins and profitability. Despite uncertainties, CVS's valuation does seem fair considering the worst is seemingly behind, leading to an upgraded rating from 'Sell' to 'Hold'. Read the full article on Seeking AlphaSeeking Alpha • Feb 26
CVS Health: Incremental Improvement Best Hope For 2025 (Rating Downgrade)
Summary CVS Health experienced a significant share price decline in 2024, driven by earnings misses, CEO departure, and regulatory pressures on its PBM and Medicare Advantage businesses. Q4 2024 earnings showed revenue growth but declining operating income and EPS, with the healthcare benefits division facing rising costs and lower profitability. The new CEO aims to improve outcomes, increase access, and lower care costs, but faces challenges such as CMS rate negotiations and activist investor pressures. Despite recent share price gains, I downgrade CVS to "Hold" due to ongoing operational challenges and uncertainties about achieving a turnaround in 2025. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Summary Despite a >10% rise in CVS Health's stock price from my initial BUY recommendation, CVS Health is downgraded to Hold due to substantial political risks and declining cash flow. CVS faces significant challenges, including DOJ lawsuits, potential business separation, political scrutiny, and declining cash flow, impacting its turnaround prospects. CVS reported strong Q4 sales and new leadership from the new CEO David Joyner may bode well for shareholders. However, political risks and ongoing industry battles make CVS Health's turnaround uncertain, warranting a conservative Hold rating despite the recent rally in its stock price. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
CVS Health Isn't Going To The Dogs
Summary CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges. I believe the cash dividend, now yielding 5 percent, remains safe. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
CVS Health: An Attractive 5.8% Safe Yield For Now
Summary Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%. With a potential upside of nearly 45%, CVS could be a compelling buy for patient investors, but I maintain a hold rating due to ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
CVS Health: When The Industry Is In Crisis, Don't Pick The Weaker Players
Summary CVS Health has struggled post-pandemic due to rising costs, regulatory scrutiny, and poor management decisions, leading to significant underperformance and multiple guidance cuts. The company's execution of its large scale acquisitions has been disappointing, resulting in record-high revenues but multi-year low operating margins. The recent CEO change and ongoing restructuring create uncertainty, making CVS an unattractive investment compared to its peers. With sector recovery expected in 2025, I recommend avoiding CVS and seeking opportunities elsewhere for better returns. Read the full article on Seeking AlphaShareholder Returns
| CVS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.4% | 1.8% | 0.8% |
| 1Y | 53.1% | 28.5% | 20.2% |
Return vs Industry: CVS exceeded the US Healthcare industry which returned 28.5% over the past year.
Return vs Market: CVS exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| CVS volatility | |
|---|---|
| CVS Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CVS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 259,500 | J. Joyner | www.cvshealth.com |
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
CVS Health Corporation Fundamentals Summary
| CVS fundamental statistics | |
|---|---|
| Market cap | US$133.62b |
| Earnings (TTM) | US$2.93b |
| Revenue (TTM) | US$405.62b |
44.4x
P/E Ratio0.3x
P/S RatioIs CVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVS income statement (TTM) | |
|---|---|
| Revenue | US$405.62b |
| Cost of Revenue | US$351.32b |
| Gross Profit | US$54.30b |
| Other Expenses | US$51.37b |
| Earnings | US$2.93b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | 2.30 |
| Gross Margin | 13.39% |
| Net Profit Margin | 0.72% |
| Debt/Equity Ratio | 81.3% |
How did CVS perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield115%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 13:32 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CVS Health Corporation is covered by 47 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Hua Ha | Baird |